HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 543,700 shares, a decrease of 34.9% from the February 13th total of 835,500 shares. Based on an average daily volume of 5,830,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.1% of the shares of the company are sold short.

HCW Biologics Stock Down 0.3 %

NASDAQ HCWB traded down $0.00 during trading hours on Monday, hitting $0.34. 86,601 shares of the stock were exchanged, compared to its average volume of 3,894,991. The company has a market cap of $15.10 million, a price-to-earnings ratio of -0.34 and a beta of 0.71. HCW Biologics has a 12-month low of $0.21 and a 12-month high of $2.52. The stock has a 50-day moving average of $0.38 and a 200 day moving average of $0.46.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.